General Session
Kathleen Gibson, MD, FACS, FAVLS
Congress President
Lake Washington Vascular Surgeons
Bellevue, Washington, United States
Disclosure(s): Boston Scientific: Consultant/Advisory Board, Other Research Support, Speaker/Honoraria; Gore: Consultant/Advisory Board, Research Grant; Janssen: Speaker/Honoraria; Koya: Consultant/Advisory Board; Medtronic: Consultant/Advisory Board, Other Research Support, Research Grant, Speaker/Honoraria; Philips: Consultant/Advisory Board, Speaker/Honoraria
Fedor Lurie, MD, PhD (he/him/his)
UIP Research Chair
Jobst Vascular Institute
University of Michigan
Toledo, Ohio, United States
Disclosure(s): This disclosure is currently undergoing the review/mitigation process and will be published momentarily.
John Blebea, MD, MBA
Clinical Professor of Surgery
Central Michigan University
Central Michigan University
Saginaw, MI, United States
Disclosure(s):
The forementioned Program Planner, Faculty, Author, Moderator, or Speaker, has declared for this educational activity, having no relevant financial relationship(s) with ineligible companies to disclose. or AVLS has reviewed / mitigated there are no relevant financial relationships with ineligible companies.
Mark Meissner, MD
Peter Gloviczki Professor of Venous and Lymphatic Disorders
University of Washington
University of Washington School of Medicine
Seattle, WA, United States
Disclosure(s):
The forementioned Program Planner, Faculty, Author, Moderator, or Speaker, has declared for this educational activity, having no relevant financial relationship(s) with ineligible companies to disclose. or AVLS has reviewed / mitigated there are no relevant financial relationships with ineligible companies.
Alun H. Davies, MA, DM, DSc, FRCS, FHEA, FEBVS, FLSW, FACPh
Professor of Vascular Surgery
Section of Vascular Surgery, Imperial College London
Imperial College
London, England, United Kingdom
Disclosure(s):
The forementioned Program Planner, Faculty, Author, Moderator, or Speaker, has declared for this educational activity, having no relevant financial relationship(s) with ineligible companies to disclose. or AVLS has reviewed / mitigated there are no relevant financial relationships with ineligible companies.